Dongkook Pharmaceutical 1Q Sales Reach 165.7 Billion KRW... Record Quarterly Revenue Achieved

[Asia Economy Reporter Chunhee Lee] Dongkook Pharmaceutical achieved its highest quarterly sales ever in the first quarter of this year.

According to the first quarter quarterly report disclosed by Dongkook Pharmaceutical on the 16th, consolidated financial statements show first quarter sales of 165.67602 billion KRW and operating profit of 23.467 billion KRW, representing increases of 15.1% and 19.4% respectively compared to the same period last year.

The company stated, "All business divisions, including the Over-the-Counter (OTC) division, Overseas Business division, Ethical Therapeutics (ETC) division, Healthcare division, and our subsidiary Dongkook Life Science, showed balanced growth."

In the OTC sector, gum medicine 'Insadol', wound treatment 'Madecassol', and oral hemorrhoid medicine 'Chisen' led growth in the first quarter, rebounding to pre-COVID-19 normal levels. In the export (Overseas Business) sector, the glycopeptide antibiotic raw material 'Teicoplanin' showed steady growth in existing export countries.

In the ETC sector, chronic disease-related internal medicine drugs such as the hyperlipidemia combination drugs ‘Rosutanjet’, ‘Pitaron-F’, and ‘Atovanduo’ led growth, and liquid osteoporosis treatment ‘Masibone S solution’ and related drugs are rapidly growing, indicating expectations for continuous sales increase.

This content was produced with the assistance of AI translation services.